Axsome Therapeutics (AXSM) Short term Debt (2016 - 2026)

Axsome Therapeutics has reported Short term Debt for 10 years, with the latest figure at $11.2 million in Q1 2026.

• Quarterly Short term Debt rose 29.62% year-over-year to $11.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.2 million (up 29.62% YoY) and the FY2025 annual result came in at $10.0 million, changed N/A from the prior year.
• Short term Debt advanced to $11.2 million in Q1 2026 per AXSM's latest filing, from $10.0 million in the prior quarter.
• Over five years, Short term Debt peaked at $11.2 million in Q1 2026 and troughed at $5.9 million in Q4 2022.
• A 5-year average of $7.6 million and a median of $7.0 million in 2022 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2023 and 2025: Short term Debt retreated 4.69% in 2023, then soared 34.66% in 2025.
• Over 5 years, Short term Debt stood at $5.9 million in 2022, then gained by 8.59% to $6.4 million in 2023, then rose by 26.91% to $8.1 million in 2024, then increased by 23.13% to $10.0 million in 2025, then increased by 11.37% to $11.2 million in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $11.2 million, $10.0 million, and $9.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.